It's no gold rush, but dozens of players are emerging in personalized medicine, with biotechs, big and small, leading the way. Some big pharma companies and even payers remain skeptical, but economics aside, the real winners will be patients.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE)
BMC Health Services Research Open Access 31 October 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
08 July 2008
In the version of this article initially published, Table 1 (page 510-511) contained two errors. In the entry for Agendia, the product Mammaprint was described as providing information on chemotherapy options for breast cancer patients. In fact Mammaprint is a prognostic test. In the entry for Genomic Health, the product Oncotype Dx was described as providing information on breast cancer recurrence. Oncotype DX also provides information on the response to chemotherapy.
References
Chase, M. Payers aim to rein in specialty-drug spending. The Wall Street Journal, 20 March 2008, p B1.
Russo, M.J. & Balekdjian, D. Nat. Biotechnol. 26, 173–182 (2008).
Amado, R.G. et al. J. Clin. Oncol. 26, 1626–1634 (2008).
Mallal, S. et al. N. Engl. J. Med. 358, 568–579 (2008).
Shiffman, D. et al. J. Am. Coll. Cardiol. 51, 444–448 (2008).
Winslow, R. Gene variant is said to be linked to heart attack and prevention. The Wall Street Journal, 22 Jan, 2008, p D3.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allison, M. Is personalized medicine finally arriving?. Nat Biotechnol 26, 509–517 (2008). https://doi.org/10.1038/nbt0508-509
Issue Date:
DOI: https://doi.org/10.1038/nbt0508-509
This article is cited by
-
Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE)
BMC Health Services Research (2013)
-
Perspectives on Systems Biology Applications in Diabetic Kidney Disease
Journal of Cardiovascular Translational Research (2012)
-
Overhauling the reimbursement system for molecular diagnostics
Nature Biotechnology (2011)
-
Personalized Medicine: Understanding Probabilities and Managing Expectations
Journal of General Internal Medicine (2011)